TARS Earnings Date: Nov 3, 2026 (Estimated) — Tarsus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TARS's next earnings date?
Tarsus Pharmaceuticals, Inc. (TARS) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.46 on revenue of $187.8M.
How did TARS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Tarsus Pharmaceuticals, Inc. posted EPS of -$0.43 versus the -$0.19 estimate, a miss of 72.0%. Revenue was $173.9M against a $169.7M estimate. The stock's 1-day post-earnings move was +6.6%.
How much does TARS stock move after earnings?
TARS beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.19 | -0.43 | -72.00% | $173.9M | ❌ Miss | +6.59% | +14.24% | +35.76% |
| 2026-05-06 | Q1 2026 | -0.39 | -0.16 | +58.97% | $162.1M | ✅ Beat | -1.24% | -0.15% | -8.46% |
| 2026-02-23 | Q4 2025 | -0.07 | -0.20 | -185.71% | $151.7M | ❌ Miss | +7.79% | +11.27% | -9.25% |
| 2025-11-04 | Q3 2025 | -0.34 | -0.30 | +11.76% | $118.7M | ✅ Beat | -4.62% | +5.79% | +14.45% |
| 2025-08-06 | Q2 2025 | -0.35 | -0.48 | -37.14% | $102.7M | ❌ Miss | +15.15% | +26.61% | +38.40% |
| 2025-02-25 | Q4 2024 | -0.82 | -0.60 | +26.83% | $66.4M | ✅ Beat | -9.33% | -6.19% | +12.71% |
| 2024-11-13 | Q3 2024 | -0.94 | -0.61 | +35.11% | $48.1M | ✅ Beat | +0.31% | +0.16% | +12.89% |
| 2024-05-08 | Q1 2024 | -1.20 | -1.01 | +15.83% | $27.6M | ✅ Beat | -8.86% | +3.08% | -13.79% |
Showing last 8 quarters.